A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

April 30, 2006

Study Completion Date

March 31, 2007

Conditions
Fabry Disease
Interventions
BIOLOGICAL

Fabrazyme (agalsidase beta)

1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months

Trial Locations (4)

51014

Tartu University Clinics, Department of Internal Medicine, Tartu

128 02

II. interní klinika 1. LF UK, Prague

04-736

"Klinika Chorob Metabolicznych, Instytut Pomnik-Centrum Zdrowia Dziecka", Warsaw

833 40

Detská fakultná nemocnica Kramáre I. Interná klinika, Bratislava

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00196716 - A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease | Biotech Hunter | Biotech Hunter